Alto Neuroscience ANRO Proceeds from sale of common stock and pre-funded warrants in 2026 private placement
Proceeds from sale of common stock and pre-funded warrants in 2026 private placement at other companies
Other financials
Where this comes from
Reported directly by Alto Neuroscience in its filing.
Tagged under the XBRL concept alto:ProceedsFromSaleOfCommonStockAndPreFundedWarrantsInPrivatePlacement.
The official record: Alto Neuroscience’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Alto Neuroscience's proceeds from sale of common stock and pre-funded warrants in 2026 private placement.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Alto Neuroscience's proceeds from sale of common stock and pre-funded warrants in 2026 private placement?
- Alto Neuroscience (ANRO) reported proceeds from sale of common stock and pre-funded warrants in 2026 private placement of $120M in Q1 2026.
- What does proceeds from sale of common stock and pre-funded warrants in 2026 private placement mean?
- Represents the gross cash inflows generated from the issuance of common equity and pre-funded warrants to investors. This metric is a primary indicator of the company's ability to raise capital to fund clinical trials and general corporate operations. It reflects investor confidence in the company's pipeline and long-term valuation.